Recent News & Research

OncLive
ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC ResearchTreatments

ADC-, Bispecific Antibody–Based Therapies Help Build a New Treatment Paradigm in EGFR+ NSCLC

*July 2025* Osimertinib's approval for NSCLC post chemoradiation is supported by the LAURA trial, showing improved overall survival compared with placebo. The ORCHARD study is evaluating osimertinib with datopotamab deruxtecan, demonstrating promising progression-free survival and response rates in EGFR-mutated NSCLC. The MARIPOSA trial showed that amivantamab plus lazertinib offers an…
laurabbook@gmail.com
March 24, 2026
OncLive
Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC ResearchTreatments

Frontline Iza-Bren Plus Osimertinib Elicits 100% ORR in EGFR-Mutant NSCLC

*September 2025* Key Takeaways Iza-bren plus osimertinib achieved a 100% objective response rate in EGFR-mutated NSCLC, with a confirmed ORR of 95% at a 2.5 mg/kg dose. The 12-month progression-free survival and overall survival rates were 92.1% and 94.8%, respectively, indicating strong efficacy. The treatment was well-tolerated, with hematologic adverse…
laurabbook@gmail.com
March 24, 2026
Bonnie Addario
AdvocacyStories

Tribute to Bonnie Addario

Written by Colleen Sturdivant Many in this community are likely familiar with Bonnie Addario and her positive impact on the lung cancer community. But many of you may not know that Bonnie was an early supporter of the EFGR Resisters. I became aware of the Bonnie J. Addario Lung Cancer…
laurabbook@gmail.com
March 24, 2026
Oncology News Central
“What I Tell My Patients:” Making Sense of New Treatment Options in EGFR-positive NSCLC StoriesTreatments

“What I Tell My Patients:” Making Sense of New Treatment Options in EGFR-positive NSCLC

*September 2025* In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, from Vanderbilt University, to talk about the complexities of treating advanced EGFR-positive non-small cell lung cancer. Dr. Lovely shares how she talks with…
Hannah Burson
March 12, 2026
COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC ResearchTreatments

COMPEL Study Shows Continuing Osimertinib Treatment Through Progression with the Addition of Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC

*September 2025* A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study showed that continuing osimertinib with the addition…
Hannah Burson
March 11, 2026
Onc Live
FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC ResearchTreatments

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC

*September 2025* Key Takeaways Iza-bren targets EGFR and HER3, showing potential in treating EGFR-mutant NSCLC after progression on EGFR TKI and platinum-based chemotherapy. The FDA's breakthrough therapy designation highlights iza-bren's potential to improve clinical outcomes for previously treated EGFR-mutated NSCLC patients. Clinical trials focus on determining the recommended phase 2…
laurabbook@gmail.com
February 20, 2026
BBC logo
Advocacy

The mystery rise of lung cancer in non-smokers

*June 2025* The number of lung cancer cases in people who have never smoked is increasing. The disease is different from lung cancer caused by smoking, so what causes it? Martha first realised that something was wrong when her cough changed and the mucus in her airways became increasingly viscous.…
laurabbook@gmail.com
November 21, 2025